Latest Content

Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and stomach cancers. Here is what each found and what it means for patients.

An expert discusses infection risks after treatment, what follow-up care looks like and why patients with a rare cancer should ask questions, seek expert opinions and find community.

Median survival, hazard ratio, progression-free survival: a plain-language guide to the terms in cancer trial news, so you can tell what a result means for you and what to ask your care team.

Dr. Robert J. Kreitman explains how an experimental CAR T-cell therapy may help patients with relapsed hairy cell leukemia achieve lasting remissions.

Dr. Jacqueline Barrientos discussed how collaboration, individualized treatment and patient advocacy helped a 72-year-old man achieve leukemia remission and receive a kidney transplant.

Adding Imdelltra to Imfinzi maintenance helped people with extensive-stage small cell lung cancer live a median of 21.1 months vs. 12.7 months with Imfinzi alone in the phase 3 DeLLphi-305 trial.

The FDA approved Talzenna plus Xtandi for adults with HRR-mutated metastatic prostate cancer that has not been treated with, or is still responding to, androgen pathway drugs.

New results for lung and pancreatic cancer show newer targeted drugs may help some patients live longer. Here is what patients and caregivers should know.

Two federal laws, the Family and Medical Leave Act and the Americans with Disabilities Act, can protect people with cancer and their caregivers at work. Here is who qualifies, what each law covers and how to ask for leave or changes at wor

After 19 years of survivorship, one cancer survivor reflects on life's changing seasons, managing scan anxiety and finding support beyond treatment.

Psychiatrist Dr. Yesne Alici of Memorial Sloan Kettering Cancer Center answers questions about family relationships during cancer, from asking for help to talking with children and friends.

Among more than 12,000 cancer survivors 65 and older, those who stayed physically active after diagnosis tended to have lower health care costs, an American Cancer Society study published Oct. 21, 2026, in CANCER found.

The FDA grants traditional approval to Keytruda and Keytruda Qlex for TMB-H solid tumors, updating the threshold to at least 13 mutations per megabase.